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INTRODUCTION
Monoamine oxidase inhibitors (MAOIs) are now reco gnized as effective
me d ications in th e treatment of major depression (1). However, th eir clin ica l use
has been limi ted by the ris k of severe hypertensive reactions to oral tyram ine
challenge. Prevention of this so-called "cheese effect " requires ad herence to
diet restrictions that can lead to problems with patient compliance to MAO Is.
L-deprenyl is a select ive MA O-B inhibitor that is reportedly free of th e
"cheese effect" (2). T his rev iew will discuss the clinical and th eoreti cal impor-
tance of this interesting drug.
PHARMACOLOGY
In 1968, Johnstone reported multiple forms of th e monoamine oxidase
(MAO) enzyme (3). MAO-A, an enzyme inhibited by the MAO I c1orgyline , is
responsible for selectively metabolizing norepinephrine and se ro ton in. MAO-B,
selectively inh ib ited by deprenyl, preferentially metabolizes phenyleth ylam ine
(PEA) and benzylarnine, with little effect on the MAO-A subst rates. Dopam ine
and tyramine a re metabolized by both types of MAO enzymes. The first
generation MAOIs (phenelzine and tran ylcypromine) non-selectively inhibit
MAO-A and MAO-B.
Deprenyl (a lso known as deprenil or se legiline) is an irreve rsible MAO-B
inhibitor (4). The levorotatory isomer is thought to be more se lective of MAO-B
inhibition and is the form most thoroughly stud ied, so that re ferences to
deprenyl in this paper refer to l-deprenyl unless otherwise specified . At doses
that are selective for MAO-B inhibition (10-30 mg/day), st ud ies of deprenyl
show no evidence of hypertensive rea ctions to 200 mg of ingested tyramine , a
considerably larger amount than found in th e usual di et (5). Dosages of great er
than 30 mg/day of deprenylleads to partial MAO-A inhibition , but neve r to th e
ex te nt of th e non-selective MAO Is.
T he mechanism for depren yl' s lack o f cheese effec t may be that, despite the
total MAO-B inhibition , th ere continues to be substantial tyr amine deamination
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by intestinal MAO (7), which is predominantly MAO-A (6). Dopam ine in the
human brain is metabolized mostly by MAO-B (8), and platelet MAO is also of
the B-type (9). Platelet MAO-B inhibition has been used as a mea sure of MAO-B
inhibition in the brain (10), but recent work casts doubt on th e co rrelation
between platelet and brain MAO activity (11). A promising new techn ique to
measure in vivo brain MAO activity utilizes positron em ission to mography and
lie-labeled selective MAOIs (12).
As expected, deprenyl administration results in a sharp r ise in urinary PEA ,
and this too can be used to measure the degree of central MAO-B inhibit ion .
The ingestion of large amounts of PEA also has no significant pressor response
in patients taking deprenyl (5).
Deprenyl has other biochemical effects in addition to MAO inhibition . It
demonstrates some blockade of norepinephrine and dopamine re uptake and
inhibition of norepinephrine release (4). Because deprenyl is metabol ized to
methamphetamine and amphetamine in humans (13), it has some dopami ne
releasing properties.
CLINICAL TRIALS
Pa rkinson' s Disease
MAOIs have been used in the treatment of Parkinson 's di sea se in conjunc-
tion with L-dopa/carbidopa . However, their use has again been limited due to
the disabling side effects of hypotension and tyramine crises.
The clinical efficacy of deprenyl as an adjunct to standard antipa rk inso nian
treatment is well documented (14). The mechanism of ac tio n is now th ought to
be inhibition of striatal dopamine oxidation by MAO-B (15 ), th ereby leading to
increased availability of dopamine, as opposed to a dopamine releasing me cha-
nism (ie. by an amphetamine-like action). The dosages used , usuall y 10- 20
mg/day, have produced no adverse effects and no hypertensive crises (16).
Because deprenyl potentiates the action of t.-dopa , th e dosage of L-dopa can
often be lowered when deprenyl is star ted. Deprenyl ma y be of particul ar ben efit
in the "off" phase of the on-off phenomenon seen in advanced stages of
Parkinson 's disease that is now recognized as part of th e di sease process rather
than a tolerance effect to long-term administration of L-dopa (17). It is a lso
more likely to benefit the "benign" forms of Parkinson's disea se and is less
effective in the malignant subtypes of this disorder.
Long-term deprenyl use in patients with Parkinson's di sease suggest that
use of deprenyI may be associated with prolonged life expec tancy, an effect no t
seen in other antiparkinsonian treatments (16 ,18,19). Depren yl has a lso been
shown to prevent the striatal neurotoxicity of MPTP (20) in animal models of
Parkinson's disease, suggesting that it may prevent progression of th e di sease at
some level.
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Clorgyline, th e selecti ve MAO-A inhibitor, has been show n to have
significant antidepressant activity. Previous double blind st udies fo und it to be as
effective as imipramine (21) . However, because clorgy line a lso has the cheese
effect, it he ld no advantage over previous MAO Is.
Since MAO-B inhibition is free of the ch eese effec t, it wou ld be of clinica l
interest if MAO-B inhibitors were effec t ive ant idepressant drugs. Early open
studies of deprenyl showed an antidepressant effect, but these studies used
higher, non-selective dosages of the MAO-B inhibitor as well as racem ic form s of
deprenyl (22). Negative results were obtained in o ne co n trolled study where
pargyline, a partially selective MAO-B inhibitor, was shown to be significantly
inferior to clo rgyline in th e treatment of major depressio n (23).
There are on ly two controlled studies of depren yl' s efficacy in depression .
Mendlewicz and Youdim (24), in a double blind study of 27 patients with
ROC-defined major depression, found a significantly greater number of pa tients
who responded to 15 mg/day of deprenyl (10/ 14 pa tients with < 50% of
pretreatment Hamilton Rating Scale [H RSJ sco re, 7/1 4 patients with < 25% of
pretreatment HRS) as compared to placebo (2/ 13 and 0/ 13 patients respec-
tively).
In contrast, Mendis et al conducted a double blind trial o f deprenyl versus
placebo in 22 patients with " m ild to moderate " unipolar depression (25). They
showed no differen ces between 20 mg/day of depren yl and placebo in th e
Hamilton scores, se lf-rat ing sca les , and globa l cl in ica l rating sca les. Although
diagnostic cr iter ia were not specified, this group's exper ience was that sim ilarly
diagnosed patients showed a 50% marked response to t ra d itiona l tricyclics
compared to the 20 % re sponse of depren yl and placebo reported in this study.
In an open trial of deprenyl, Mann et a l (26) reported th at 16/ 25
ROC-defined depressed patients responded to 10- 20 mg/day of depren yl
(respo nse = < 50% pretreatment HRS).
Atypical Depression
MAO Is have traditionall y been tho ugh t to be most effective for so-call ed
" a typ ical depressions" (27), and some evidence exists th at perhaps depren yl is
more effect ive in th is sub-type of depressive illn ess .
Mendlewicz and Youdim noted a non-significant trend of the ir depren yl
respo nders have " atypica l symptoms" (neurotic, anx ious and somatic features)
(17) .
Mann e t al in their open stu dy (26) showed a trend (p < 0.10) for more
deprenyl responders among " nonendogenous" depressives as defined by th e
Newcastle Scale (10 / 12 non-endogenous vs 6/1 3 endogenous). Both groups
showed significant reduction of Hamilton scores a fte r 21 days of treatment but
th e non-endogenous group responded afte r on ly 7 days. T he non-endogenous
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group also had lower HRS scores overall , but it is unclear from their data if thi s
was statistically significant. Fewer unipolar endogenous depressives seemed to
respond compared to bipolar, but not at statistically significant levels.
In an open trial of deprenyl in atypical depressives, Quitk in et al (28 ) found
that 10/17 responded (m uch improved or better on th e CG I). Compared to a
placebo group in a parallel double-blind study of phenelzine-imip ram ine-
placebo, however, the re was only a trend to superiori ty of depre nyl (p < 0 .10).
Of the 10 responders, 9 required doses of30 mg/day, whi ch th e investigators
felt was perhaps not selective for MAO-B alone.
SUMMARY OF CLI NICAL TRIALS
While it is clear th at deprenyl is an effec t ive anti parkinsonian drug, its
antidep ressa nt efficacy is still in question. T he two co ntrolled studies show
co nflict ing results while open stu d ies have been more encouraging, particula rly
in the treatment of atyp ical, non-endogenous depression. It should be noted that
th e two stud ies showing negative results with MAO-B inhibito rs used depressed
patients with "endogenous" symptoms, a populati on whic h may be less respon-
sive to MAOIs (23,25). Future co ntro lled stud ies shou ld incorpora te subtyping
of depression or compa re deprenyl to non-selecti ve MAO Is.
PSYCHOBIOLOGY OF DEPRESSION
.lf depren yl is an effecti ve antidepressant, what migh t be its mechanism o f
action? Sin ce depren yl is metabolized to methamphetami ne and amphetamine ,
and becau se deprenyl is reported to have a faster onset of action than other
MAO Is, one might suspect that its antidepressant effect is simp ly due to
amphetam ine. L-deprenyl is presumably metabolized to I-amphe tamine , wh ich
is thought to be less euphoria-produc ing than its isomer, d-amphetam ine (29) . In
Quitkin e t aI' s study (28), 7/8 patients showing pre- treatmen t dysphoric
responses to amphetamine administration responded to deprenyl , while only
3/ 7 showing e uphor ia responded to deprenyl. T hus, it may no t be the amphe ta-
mine-like ac tion of deprenyl that is responsible fo r its antidepressant e ffect.
An other interesting finding was th at no t o nly did depren yl increase urina ry
PEA , but it a lso significantly d ecreased urinary MHPG whe n no effect would be
expe cted (30). In addition , those patients with th e lowest baseli ne MHPG levels
appeared to be th e ones to respond to deprenyl. Thus, depren yI's antidepressant
action ma y be mediated through bioch emical e ffec ts o ther th an the MAO-B
inhibition.
Mendlewicz and Youdim (24) fo u nd th at depren yl res ponders had a greater
degree of platelet MAO-B inh ibition wh en co mpared to non-responders. How-
ever, other investigators have shown that inh ibition of greate r than 80 % of
platelet MAO-B consistently occurs eve n with short term admin istrat io n of 10
mg of depren yl (31).
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What if deprenyl is not an effective antidepressant? Knowing that clorgylin e is
effective, this could mean that MAO-A inhibition is the essential mech anism fo r
the antidepressant effect. This hypothesis has been forwarded by severa l
investigators (23,25), and is more consistent with the monoamine hypothesis of
depression since norepinephrine and serotonin, the neurotransmitters tradi-
tionally linked to the psychobiology of depression, are metabolized by MAO-A.
Some studies show that only higher doses of deprenyl are effec tive agains t
depression, when MAO-A may also be inhibited (28). If MAO-B inh ibition was
the critical factor, then one would expect lower doses of depren yl, producing
almost complete platelet MAO-B inhibition (31), to be equally effective. O ther
investigators have suggested that the antidepressant effect of MAOIs shares the
same mechanism as the cheese effect , postulating that th e effect is mediated
through enhancement of central norepinephrine release due to trace amounts
of tyramine acting on central synapses (25).
CONCLUSION
L-deprenyl, a se lective MAO-B inhibitor, is an effective ad junct ive treat-
ment for Parkinson's disease. However, evidence that se lect ive MAO-B inh ibi-
tors are as effective as non-selective MAOIs in the treatment of depression
remains inconclusive, although there is suggestion that deprenyl ma y be effec-
tive in "atypical depression. " Deprenyl is not yet commercially available, but
further studies are warranted because the lack of a cheese effect co nfers a
significant advantage over other MAOIs that would make deprenyl an impor-
tant addition to our antidepressant armamentarium. Furthermore , by using
selective MAO inhibitors such as clorgyline and deprenyl as psychopharmaco-
logical probes we can glean further insights into th e psychobiology of depressive
disorders.
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